CRISPR Therapeutics AG
CRSP · NASDAQ
$49.88+$0.14 (+0.28%)TodayMarket closed ·
Prev close $49.74
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 27.2% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$1.06
- Revenue estimate
- $15.24M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.22 | -$0.94 | +23.0% |
| Q1 FY26 | -$1.25 | -$1.28 | −2.5% |
| Q4 FY25 | -$1.18 | -$1.37 | −16.4% |
| Q3 FY25 | -$1.29 | -$1.17 | +9.0% |
| Q2 FY25 | -$1.45 | -$1.29 | +11.2% |
| Q1 FY25 | -$1.28 | -$1.58 | −23.9% |
| Q4 FY24 | -$1.19 | -$0.44 | +63.0% |
| Q3 FY24 | -$1.44 | -$1.01 | +29.8% |
Earnings calls
- Morgan Stanley 24th Annual Global Healthcare Conference
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- 46th Annual William Blair Growth Stock Conference
- Jefferies Global Healthcare Conference 2026
- Bank of America Global Healthcare Conference 2026
- 25th Annual Needham Virtual Healthcare Conference
- Citi’s 2026 Virtual Oncology Leadership Summit
- 44th Annual J.P. Morgan Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.